Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI8111 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | MEDI8111 |
| B | PLACEBO_COMPARATOR | Placebo for MEDI8111 |
| Name | Type | Description |
|---|---|---|
| MEDI8111 | DRUG | MEDI8111 lyophilisate for solution for infusion |
| Placebo | OTHER | Placebo for MEDI8111 saline solution for infusion |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures, Healthy male subjects aged 18-40 years with suitable veins for cannulation or repeated venepuncture, Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weight at lea...
MEDI8111 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult male subjects in the United Kingdom. The specific disease or condition it is intended to treat has not been publicly disclosed.
MEDI8111 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 1 study of the compound conducted in the United Kingdom.
MEDI8111 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA for any indication.
MEDI8111 was evaluated in a single Phase 1 trial, NCT01958645, titled a study to assess safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending doses. The trial enrolled 157 healthy male subjects in the United Kingdom and has been completed.
The Phase 1 trial NCT01958645 was a randomized, placebo-controlled study of intravenous MEDI8111 given as single ascending doses. It enrolled 157 healthy male volunteers aged 18 years and older in the United Kingdom. The study was not double-blind and has been completed.